BridgeBio, a biotech known for its model of setting up subsidiaries to house its R&D programs, is splitting off its oncology unit with $200 million in support from 11 investors.
Cormorant Asset Management, which backed BridgeBio as a startup, led the financing for the spinout, which will be known as…
Click here to view original post
Click Here to Publish/Feature Your Company or Product News with Biotech Networks
